[Minohua: rosuvastatin calcium route II raw material drug obtained European CEP certificate] Minovale announced that it has received an European CEP certificate (European Pharmacopoeia applicability Certificate) issued by the European Drug quality Administration (EDQM) for rosuvastatin calcium route II (API). Rosuvastatin calcium (API) is one of the company's key products, this time the drug has obtained the CEP certificate, which provides the company with a competitive basis and advantage to further expand the international market.